GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (MEX:INO) » Definitions » Shiller PE Ratio

Inovio Pharmaceuticals (MEX:INO) Shiller PE Ratio : (As of Jun. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inovio Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Shiller PE Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inovio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Shiller PE Ratio falls into.



Inovio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Inovio Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Inovio Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-21.741/131.7762*131.7762
=-21.741

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -29.570 100.560 -38.749
201409 -19.335 100.428 -25.370
201412 -21.240 99.070 -28.252
201503 -32.929 99.621 -43.558
201506 -16.945 100.684 -22.178
201509 14.194 100.392 18.631
201512 -53.648 99.792 -70.842
201603 -22.722 100.470 -29.802
201606 -57.700 101.688 -74.773
201609 -64.967 101.861 -84.047
201612 -89.065 101.863 -115.220
201703 -70.044 102.862 -89.733
201706 -28.199 103.349 -35.955
201709 -87.110 104.136 -110.232
201712 -56.562 104.011 -71.661
201803 -78.484 105.290 -98.227
201806 -18.864 106.317 -23.381
201809 -60.604 106.507 -74.983
201812 -82.467 105.998 -102.523
201903 -69.833 107.251 -85.802
201906 -69.152 108.070 -84.322
201909 -59.226 108.329 -72.045
201912 -86.002 108.420 -104.529
202003 -73.158 108.902 -88.525
202006 -229.898 108.767 -278.531
202009 29.160 109.815 34.992
202012 -26.257 109.897 -31.485
202103 -66.229 111.754 -78.095
202106 -93.160 114.631 -107.093
202109 -71.556 115.734 -81.474
202112 -124.110 117.630 -139.036
202203 -86.016 121.301 -93.444
202206 -111.051 125.017 -117.055
202209 -36.207 125.227 -38.101
202212 -49.715 125.222 -52.317
202303 -34.067 127.348 -35.252
202306 -26.744 128.729 -27.377
202309 -27.173 129.860 -27.574
202312 -17.823 129.419 -18.148
202403 -21.741 131.776 -21.741

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (MEX:INO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Inovio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (MEX:INO) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.